04/29/2026 15:39 – Other information

The first quarter of 2026 was a record for the number of fillings and revenues for the first quarter of the year. At this time, the Company remains committed to its revenue projection for 2026. In 2026, the Company expects revenues in the range of €1.1 million – €1.5 million. This means an increase in revenue of 2 to 2.6 times higher than the previous business year.

Download document

03/31/2026 16:04 – Inside information

enasolAuto d.o.o., as the owner of the Qelo brand and electric vehicle charging system, hereby informs the market that a process has been initiated for the sale of a 10% ownership stake in enasolAuto d.o.o. An existing shareholder (Enasol d.o.o.) is selling its 10% stake to a special purpose vehicle (SPV – Qorex One d.o.o.).

Download document

03/10/2026 14:30 – Other information

enasolAuto has changed its business residence. The new adress is: enasolAuto d.o.o. Selska cesta 136 10000 Zagreb Republika Hrvatska

Download document

02/23/2026 07:44 – Other information

Business results in 2025. and guidance for2026.

Download document

07/28/2025 08:45 – Inside information

Glucodent Ltd. has, through the company Maiwald GmbH, submitted its second patent application to the European Patent Office in order to protect its intellectual property. By submitting this second patent application, the prerequisites for the next phase of product development—clinical trials—have been established.

Download document

05/13/2025 12:01 – Other information

"GLUCODENT d.o.o., hereby notifies that on May 9, 2025, an increase in the Company’s share capital was registered in the court register of the Commercial Court in Zagreb — from the amount of EUR 7,590.00, by an amount of EUR 410.00, to a total of EUR 8,000.00, fully paid in cash.

Download document

04/04/2025 14:19 – Inside information

Glucodent Ltd, through the company Maiwald GmbH, has submitted a patent application to the European Patent Office to protect its intellectual property for a synthesized molecule that forms the foundation of Glucodent’s future medical product.

Download document

10/15/2024 13:24 – Inside information

Glucodent Ltd. has successfully completed the examination of the effect of the API on the growth and development (proliferation) of pathogenic bacteria in the oral cavity with positive results.

Download document

09/23/2024 11:14 – Inside information

Glucodent Ltd. has successfully completed the examination of the effect of the API on the pH of artificial saliva. The results obtained show that the action of the API exceeds the initial goals set by the scientists involved in the development of the GLUCODENT© product.

Download document

07/31/2024 12:42 – Inside information

Glucodent Ltd. and IQVIA have signed an agreement to develop a "Data Informed Protocol Assessment" for an oral pathology product in diabetics

Download document

07/15/2024 16:29 – Inside information

Glucodent Ltd. has successfully synthesized various APIs to form the basis for further research on the medical product for treating oral pathology in diabetics.

Download document

07/17/2012 14:46 – Općenita propisana informacija

06/19/2012 15:32 – Inside and other information

Download document

06/18/2012 14:55 – Općenita propisana informacija

Nexe grupa d.d. delivered notice on General Meeting to be held on 19.06.2012.

Download document

06/14/2012 09:13 – Inside and other information

Download document